Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Use of Inhaled Corticosteroids and Risk of Acquiring Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock

    Research output: Contribution to journalReviewResearchpeer-review

  • Mariann Gyöngyösi
  • Evgeny Pokushalov
  • Aleksander Romanov
  • Emerson Perin
  • Joshua M Hare
  • Jens Kastrup
  • Francisco Fernández-Avilés
  • Ricardo Sanz-Ruiz
  • Anthony Mathur
  • Wojcieh Wojakowski
  • Enca Martin-Rendon
  • Noemi Pavo
  • Imre J Pavo
  • Rayyan Hemetsberger
  • Denise Traxler
  • Andreas Spannbauer
  • Paul M Haller
View graph of relations

Individual patient data (IPD)-based meta-analysis (ACCRUE, meta-analysis of cell-based cardiac studies, NCT01098591) revealed an insufficient effect of intracoronary cell-based therapy in acute myocardial infarction. Patients with ischemic heart failure (iHF) have been treated with reparative cells using percutaneous endocardial, surgical, transvenous or intracoronary cell delivery methods, with variable effects in small randomized or cohort studies. The objective of this meta-analysis was to investigate the safety and efficacy of percutaneous transendocardial cell therapy in patients with iHF. Two investigators extracted the data. Individual patient data (IPD) (n = 8 studies) and publication-based (n = 10 studies) aggregate data were combined for the meta-analysis, including patients (n = 1715) with chronic iHF. The data are reported in accordance with PRISMA guidelines. The primary safety and efficacy endpoints were all-cause mortality and changes in global ejection fraction. The secondary safety and efficacy endpoints were major adverse events, hospitalization and changes in end-diastolic and end-systolic volumes. Post hoc analyses were performed using the IPD of eight studies to find predictive factors for treatment safety and efficacy. Cell therapy was significantly (p < 0.001) in favor of survival, major adverse events and hospitalization during follow-up. A forest plot analysis showed that cell therapy presents a significant benefit of increasing ejection fraction with a mean change of 2.51% (95% CI: 0.48; 4.54) between groups and of significantly decreasing end-systolic volume. The analysis of IPD data showed an improvement in the NYHA and CCS classes. Cell therapy significantly decreased the end-systolic volume in male patients; in patients with diabetes mellitus, hypertension or hyperlipidemia; and in those with previous myocardial infarction and baseline ejection fraction ≤ 45%. The catheter-based transendocardial delivery of regenerative cells proved to be safe and effective for improving mortality and cardiac performance. The greatest benefit was observed in male patients with significant atherosclerotic co-morbidities.

Original languageEnglish
Article number3205
JournalJournal of Clinical Medicine
Volume11
Issue number11
ISSN2077-0383
DOIs
Publication statusPublished - 4 Jun 2022

ID: 78746006